Cargando…

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner

INTRODUCTION: Soluble antigens complexed with immunoglobulin G (IgG) antibodies can induce robust adaptive immune responses in vitro and in animal models of disease. Factor VIII immune complexes (FVIII-ICs) have been detected in individuals with hemophilia A and severe von Willebrand disease followi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Batsuli, Glaivy, Ito, Jasmine, York, Elizabeth S., Cox, Courtney, Baldwin, Wallace, Gill, Surinder, Lollar, Pete, Meeks, Shannon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501482/ https://www.ncbi.nlm.nih.gov/pubmed/37720212 http://dx.doi.org/10.3389/fimmu.2023.1233356

Ejemplares similares

Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow
por: Parker, Ernest T., et al.
Publicado: (2021)

Subunit Flexibility of Multimeric von Willebrand Factor/Factor VIII Complexes
por: Parker, Ernest T., et al.
Publicado: (2022)

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII
por: Grushin, K, et al.
Publicado: (2014)

Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2020)

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway
por: Patel, Seema R., et al.
Publicado: (2022)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells
por: Sakurai, Yoshihiko, et al.
Publicado: (2013)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation
por: Healey, J. F., et al.
Publicado: (2018)

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor
por: Childers, Kenneth C., et al.
Publicado: (2023)

Platelet Function and Factor VIII in Uremia(*)
por: Park, Hee Sook, et al.
Publicado: (1987)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor
por: Ronayne, Estelle K., et al.
Publicado: (2021)

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
por: Zerra, Patricia E., et al.
Publicado: (2020)

Cogne VIII
por: CERN. Geneva. SPS-LEAR Experiments Committee
Publicado: (1995)

Enrique VIII
por: Bowle, John
Publicado: (1970)

Enrique VIII
por: Erlanger, Philippe, 1903-1987

Hæmatology—VIII
Publicado: (1910)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Acquired Factor VIII Inhibitors: Three Cases
por: Kyaw, Tay Za, et al.
Publicado: (2013)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
por: Scott, David W., et al.
Publicado: (2020)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking
por: Ebberink, Eduard H.T.M., et al.
Publicado: (2017)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
por: Sudheesh, K. M., et al.
Publicado: (2016)

King Henry VIII /
por: Shakespeare, William, 1564-1616
Publicado: (1968)

Enlargements of the Spleen—VIII
Publicado: (1908)

Enlargements of the Liver.—VIII
Publicado: (1910)

Nature Notes—VIII
Publicado: (1910)

Chapter VIII. Of Tokens
Publicado: (1894)

Subcellular platelet factor VIII antigen and von Willebrand factor
Publicado: (1975)

Situations, VIII : Autour de 68
por: Sartre, Jean-Paul, 1905-1980
Publicado: (1972)

VIII International Congress of the Metastasis Research Society
por: Taylor, Gill, et al.
Publicado: (2001)

Factor VIII haplotypes frequencies in Tunisian hemophiliacs A
por: Elmahmoudi, Hejer, et al.
Publicado: (2011)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Blood Clotting Factor VIII: From Evolution to Therapy
por: Orlova, N. A., et al.
Publicado: (2013)

Different impact of factor VIII products on inhibitor development?
por: van den Berg, H. Marijke
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_haglm78u7tvc6pgjfpporolag3